

Sebastien Maury

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2955473/publications.pdf>

Version: 2024-02-01

142
papers

5,554
citations

117571

34
h-index

85498

71
g-index

147
all docs

147
docs citations

147
times ranked

6813
citing authors

#	ARTICLE	IF	CITATIONS
1	Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Hematology and Oncology</i> , 2022, 15, 27.	6.9	12
2	TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation. , 2022, 10, e003508.		10
3	Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT. <i>Lancet Haematology,the</i> , 2022, 9, e318-e321.	2.2	10
4	Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. <i>Scientific Reports</i> , 2022, 12, 7140.	1.6	45
5	Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study. <i>Leukemia</i> , 2021, 35, 893-896.	3.3	3
6	Scoring system for clinically significant CMV infection in seropositive recipients following allogeneic hematopoietic cell transplant: an SFGM-TC study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1305-1315.	1.3	13
7	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. <i>Blood</i> , 2021, 137, 524-532.	0.6	33
8	A rationale to prioritise vaccination of HSCT patients against COVID-19. <i>Lancet Haematology,the</i> , 2021, 8, e163-e164.	2.2	7
9	Allogeneic haematopoietic stem cell transplantation from SARS-CoV-2 positive donors. <i>Lancet Haematology,the</i> , 2021, 8, e167-e169.	2.2	24
10	Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. <i>Lancet, The</i> , 2021, 398, 298-299.	6.3	97
11	Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT. <i>Lancet Haematology,the</i> , 2021, 8, e681-e683.	2.2	66
12	Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial. <i>Blood</i> , 2021, 138, 3478-3478.	0.6	3
13	Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2. <i>Blood</i> , 2021, 138, 1232-1232.	0.6	10
14	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. <i>Blood</i> , 2021, 138, 2920-2920.	0.6	1
15	Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group. <i>Blood</i> , 2021, 138, 62-62.	0.6	23
16	Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. <i>Haematologica</i> , 2020, 105, 91-101.	1.7	86
17	Antipneumococcal Seroprotection Years After Vaccination in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, e301-e307.	2.9	9
18	Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease. <i>Blood Advances</i> , 2020, 4, 2501-2515.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Long-Term Immunity to Measles after Allogeneic Hematopoietic Cell Transplantation: Factors Associated with Seroprotection before Revaccination. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 985-991.	2.0	1
20	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. <i>Leukemia</i> , 2020, 34, 1730-1740.	3.3	21
21	Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2020, 11, 579151.	2.2	1
22	Toxoplasmosis as an Early Complication of Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2510-2513.	2.0	13
23	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. <i>Blood</i> , 2019, 134, 1351-1355.	0.6	89
24	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	2.5	72
25	Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines?. <i>Bone Marrow Transplantation</i> , 2019, 54, 1082-1088.	1.3	12
26	Mainly Post-Transplant Factors Are Associated with Invasive Aspergillosis after Allogeneic Stem Cell Transplantation: A Study from the Surveillance des Aspergilloses Invasives en France and Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 354-361.	2.0	23
27	Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 184, 294-298.	1.2	7
28	The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL). <i>Blood</i> , 2019, 134, 1339-1339.	0.6	2
29	The Absolute Count of Circulating, Classical, CD14++/CD16- Monocytes Is a Poor Prognosis Marker in Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 4242-4242.	0.6	0
30	Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 3338-3338.	0.6	0
31	A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. <i>Blood</i> , 2018, 131, 717-732.	0.6	240
32	De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1931-1940.	1.3	52
33	Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 10.	2.2	52
34	Nilotinib (Tasigna�) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02). <i>Blood</i> , 2018, 132, 31-31.	0.6	36
35	Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2017, 52, 689-696.	1.3	31
36	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e184-e186.	1.7	6

#	ARTICLE	IF	CITATIONS
37	Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?. <i>Blood</i> , 2017, 129, 1227-1230.	0.6	11
38	Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Soci�t� Fran�saise de Greffe de Moelle Osseuse et Th�rapie Cellulaire and Eurocord. <i>Bone Marrow Transplantation</i> , 2017, 52, 1428-1435.	1.3	16
39	Plasma concentrations of atovaquone given to immunocompromised patients to prevent <i>Pneumocystis jirovecii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2602-2606.	1.3	14
40	Molecular Demonstration of a <i>Pneumocystis</i> Outbreak in Stem Cell Transplant Patients: Evidence for Transmission in the Daycare Center. <i>Frontiers in Microbiology</i> , 2017, 8, 700.	1.5	17
41	Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients. <i>BMC Infectious Diseases</i> , 2017, 17, 747.	1.3	41
42	Profound lymphopenia is associated with a lower risk of hepatic cytolysis during antithymocyte globulin administration. <i>American Journal of Hematology</i> , 2016, 91, E276-8.	2.0	0
43	Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors. <i>Transplantation</i> , 2016, 100, 1732-1739.	0.5	12
44	Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. <i>Blood</i> , 2016, 128, 1651-1659.	0.6	109
45	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 1044-1053.	13.9	270
46	Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. <i>Haematologica</i> , 2016, 101, 884-890.	1.7	30
47	Specific T cells for the treatment of cytomegalovirus and/or adenovirus in the context of hematopoietic stem cell transplantation. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 920-924.e3.	1.5	21
48	Donor Immunization Against Human Leukocyte Class II Antigens is a Risk Factor for Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 292-299.	2.0	20
49	Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no�treatment study. <i>American Journal of Hematology</i> , 2016, 91, 366-370.	2.0	110
50	Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2016, 51, 358-364.	1.3	7
51	Reduced-Intensity and Non-Myeloablative Allogeneic Stem Cell Transplantation from Alternative HLA-Mismatched Donors for Hodgkin's Lymphoma: A Study By the SFGM-TC (Francophone Society of Tj ETQq1 1 @784314 rgBT /Ov		
52	A Composite Event-Free Survival End Point to Evaluate Outcome after Allogeneic Transplantation for Severe Aplastic Anemia: A Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). <i>Blood</i> , 2016, 128, 2674-2674.	0.6	0
53	Single HLA Mismatch Unrelated Donor Allogeneic Stem Cell Transplantation in Caucasian Recipients: Outcomes in HLA-A, -B, -C, -DRB1 and -DQB1 Mismatch Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society for Histocompatibility and Immunogenetics (SFHI). <i>Blood</i> , 2016, 128, 3474-3474.	0.6	0
54	Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 2486-2496.	0.6	233

#	ARTICLE	IF	CITATIONS
55	Generation of Human Alloantigen-Specific Regulatory T Cells under Good Manufacturing Practice-Compliant Conditions for Cell Therapy. <i>Cell Transplantation</i> , 2015, 24, 2527-2540.	1.2	24
56	Risk Factors and Scoring System for Predicting Bacterial Resistance to Cefepime as Used Empirically in Haematology Wards. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	3
57	Decreased Nonrelapse Mortality after Unrelated Cord Blood Transplantation for Acute Myeloid Leukemia Using Reduced-Intensity Conditioning: A Prospective Phase II Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 445-453.	2.0	29
58	Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 3711-3719.	0.6	291
59	Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy. <i>Bone Marrow Transplantation</i> , 2015, 50, 1586-1588.	1.3	8
60	Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. <i>European Journal of Haematology</i> , 2015, 94, 449-455.	1.1	10
61	Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study. <i>Blood</i> , 2015, 126, 1-1.	0.6	29
62	Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). <i>Blood</i> , 2015, 126, 3208-3208.	0.6	2
63	RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO & SFGM-TC) Tj ETQq16l 0.784314 rgB		
64	Impact of NK Cell Reconstitution and Recipient HLA-C Typing on Clinical Outcome after Reduced Intensity Cord Blood Transplant: Results of a Prospective Phase II Multicentric Trial on Behalf of Societe Francaise De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord. <i>Blood</i> , 2015, 126, 4393-4393.	0.6	0
65	Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2014, 49, 361-365.	1.3	15
66	Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease. <i>Immunology Letters</i> , 2014, 162, 173-184.	1.1	28
67	Regulatory T-cell depletion in donor lymphocyte infusions for haematological malignancies: long-term outcomes from a prospective study. <i>British Journal of Haematology</i> , 2014, 166, 452-455.	1.2	5
68	Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study. <i>Leukemia</i> , 2014, 28, 2406-2410.	3.3	16
69	Pneumococcal immunization in immunocompromised hosts: where do we stand?. <i>Expert Review of Vaccines</i> , 2014, 13, 59-74.	2.0	16
70	New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor. <i>Blood</i> , 2014, 124, 2613-2614.	0.6	10
71	Nilotinib (Tasigna�) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02). <i>Blood</i> , 2014, 124, 798-798.	0.6	31
72	Effect of Immune Modulation for Peripheral T-Cell Lymphoma in Response to Relapse after Allogeneic Hematopoietic Stem Cell Transplant: A Study of 63 Patients By the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).. <i>Blood</i> , 2014, 124, 3963-3963.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Allogeneic Stem Cell Transplantation (Allo-SCT) for De Novo Ph+ Acute Myeloid Leukemia: A Study from the French Society of Bone Marrow Transplantation and Cell Therapies. <i>Blood</i> , 2014, 124, 1232-1232.	0.6	5
74	Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning. <i>Bone Marrow Transplantation</i> , 2013, 48, 196-197.	1.3	11
75	Toward a <i>NOTCH1/FBXW7/RAS/PTEN</i>-Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 4333-4342.	0.8	202
76	Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: A case report. <i>Experimental Hematology</i> , 2013, 41, 505-507.	0.2	9
77	Double umbilical cord blood transplantation for hematological malignancies: A long-term analysis from the SFGM-TC registry. <i>Experimental Hematology</i> , 2013, 41, 924-933.	0.2	25
78	The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1409-1414.	1.3	63
79	A new workflow for the microbiological diagnosis of febrile neutropenia in patients with a central venous catheter. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 943-946.	1.3	6
80	Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia. <i>American Journal of Hematology</i> , 2013, 88, 868-873.	2.0	10
81	Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. <i>Haematologica</i> , 2013, 98, 776-783.	1.7	38
82	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adults With Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL): Results From The Group For Research On Adult ALL (GRAALL). <i>Blood</i> , 2013, 122, 552-552.	0.6	17
83	Performance of Serum Biomarkers for the Early Detection of Invasive Aspergillosis in Febrile, Neutropenic Patients: A Multi-State Model. <i>PLoS ONE</i> , 2013, 8, e65776.	1.1	27
84	Lymphodepletion Followed By Suicide-Gene-Transduced Donor Lymphocyte Infusion: A Strategy To Safely Enhance The Graft-Versus-Tumor Effect. <i>Blood</i> , 2013, 122, 153-153.	0.6	0
85	Reconstitution Of NK Cells After Reduced Intensity Conditioned Unrelated Cord Blood Transplantation In Patients With Acute Myeloid Leukemia: Analysis Of a Prospective Phase II Multicentric Trial On Behalf Of Societe FranÃ§aise De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord. <i>Blood</i> , 2013, 122, 4606-4606.	0.6	0
86	Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy. <i>Haematologica</i> , 2012, 97, 1678-1685.	1.7	13
87	Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. <i>Blood</i> , 2012, 119, 2474-2477.	0.6	14
88	Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 289-294.	2.0	51
89	Hemophagocytic syndrome after allogeneic hematopoietic cell transplantation: more a graft rejection than an infectious process?. <i>European Journal of Haematology</i> , 2012, 88, 458-460.	1.1	10
90	Is Less Chemotherapy Detrimental in Adults with Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with High-Dose Imatinib? Results of the Prospective Randomized Graaph-2005 Study. <i>Blood</i> , 2012, 120, 138-138.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT). <i>Blood</i> , 2012, 120, 3561-3561.	0.6	10
92	Anti CMV and/or Anti Adenovirus IFN-g-Positive CD4+ CD8+ T Lymphocytes for Treatment of Viral Infections After Allogeneic HSC Transplantation: First Results. <i>Blood</i> , 2012, 120, 1906-1906.	0.6	0
93	Towards a Purely Oncogenetic Risk Classification of Adult T-ALL: a GRAALL Study. <i>Blood</i> , 2012, 120, 881-881.	0.6	0
94	Influence of Nucleated Cell Dose on Overall Survival of Unrelated Cord Blood Transplantation for Patients with Severe Acquired Aplastic Anemia: A Study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 78-85.	2.0	100
95	Regulatory T Cell Content in the Bone Marrow Graft Does Not Predict the Occurrence of Acute GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 265-269.	2.0	24
96	Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. <i>Haematologica</i> , 2011, 96, 337-341.	1.7	72
97	Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry. <i>Journal of Clinical Oncology</i> , 2011, 29, 1342-1348.	0.8	196
98	Clofarabine as a potential stimulant of alloreactivity. <i>Bone Marrow Transplantation</i> , 2011, 46, 1393-1394.	1.3	4
99	Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 324-328.	1.7	98
100	L-asparaginase for adult CD20 positive B-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 1042-1042.	1.7	2
101	Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. <i>British Journal of Haematology</i> , 2010, 148, 791-796.	1.2	63
102	CD4 ⁺ CD25 ⁺ Regulatory T Cell Depletion Improves the Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Science Translational Medicine</i> , 2010, 2, 41ra52.	5.8	83
103	Retrospective Survey on the Prevalence and Outcome of Prior Autoimmune Diseases in Patients with Aplastic Anemia Reported to the Registry of the European Group for Blood and Marrow Transplantation. <i>Acta Haematologica</i> , 2010, 124, 19-22.	0.7	5
104	Updated guidelines for managing fungal diseases in hematology patients. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 1049-1060.	2.0	6
105	Allogeneic Hematopoietic Stem-Cell Transplantation In Early Phase Might Overcome the Adverse Prognosis of Acute Myeloid Leukemia with Translocation t(6;9)(p23;q34)/DEK-NP214(CAN) Rearrangement. A Retrospective Analysis From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2010, 116, 3501-3501.	0.6	1
106	Reduced Intensity Conditioning Regimen Prior to Unrelated Cord Blood Transplantation In Patients with Acute Myeloid leukemia : Preliminary Analysis of a Prospective Phase II Multicentric Trial on Behalf of Societe Française De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord. <i>Blood</i> , 2010, 116, 911-911.	0.6	2
107	Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. <i>Oncotarget</i> , 2010, 1, 34-42.	0.8	115
108	A Pediatric Treatment of Ph-Negative Acute Lymphoblastic Leukemia (ALL) Is Effective and Safe In Adolescents and Young Adults (AYAs) until 29 Years of Age. <i>Blood</i> , 2010, 116, 2125-2125.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Empirical versus Preemptive Antifungal Therapy for High-Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2009, 48, 1042-1051.	2.9	356
110	Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. <i>Haematologica</i> , 2009, 94, 1312-1315.	1.7	118
111	Clinical grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene: authors' reponse. <i>Journal of Gene Medicine</i> , 2009, 11, 737-738.	1.4	1
112	Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. <i>Clinical Microbiology and Infection</i> , 2009, 15, 81-86.	2.8	78
113	Long-Term Results of the Imatinib GRAAPH-2003 Study in Newly-Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia... <i>Blood</i> , 2009, 114, 3080-3080.	0.6	7
114	Preparation of Human Alloantigen-Specific Natural Regulatory T-Cells for the Control of Graft Versus Host Disease.. <i>Blood</i> , 2009, 114, 47-47.	0.6	0
115	Impact of Nucleated Cell Dose On Engraftment and Survival After Unrelated Cord Blood Transplantation for Severe Aplastic Anemia: A Retrospective Study On Behalf of Eurocord and the EBMT SAA WP.. <i>Blood</i> , 2009, 114, 3201-3201.	0.6	0
116	How to Improve Microbacterial Documentation in Febrile Neutropenia: Impact of Reduced Time Between Collection and Incubation, and New Technics of Identification.. <i>Blood</i> , 2009, 114, 4309-4309.	0.6	0
117	Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene. <i>Journal of Gene Medicine</i> , 2008, 10, 834-846.	1.4	19
118	Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. <i>Blood</i> , 2008, 112, 3099-3106.	0.6	313
119	Donor Regulatory T Cells Identified by FoxP3 Expression but Also by the Membranous CD4+CD127low/neg Phenotype Influence Graft-versus-tumor Effect After Donor Lymphocyte Infusion. <i>Journal of Immunotherapy</i> , 2008, 31, 806-811.	1.2	16
120	First Results of the GRAAPH-2005 Study in younger Adult Patients with De Novo Philadelphia Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 12-12.	0.6	12
121	Double Cord Blood Cell (CBC) Hematopoietic Stem Cell Transplantation after Standard or Reduced Intensity Conditioning: Report of the SFGMTC Registry.. <i>Blood</i> , 2008, 112, 1972-1972.	0.6	2
122	Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study. <i>Blood</i> , 2008, 112, 763-763.	0.6	10
123	Does the Occurrence of Invasive Fungal Infection in Acute Leukemia Patients, Impact on the Chemotherapy Schedule and Event-Free Survival? a Case-Control Study. <i>Blood</i> , 2008, 112, 3980-3980.	0.6	0
124	Subcutaneous Alemtuzumab Is a Safe and Effective Treatment for Global or Single-Lineage Immune-Mediated Marrow Failures: a Survey from the EBMT-WPSAA. <i>Blood</i> , 2008, 112, 1042-1042.	0.6	8
125	Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. <i>Blood</i> , 2007, 109, 1408-1413.	0.6	300
126	Successful Non-Myeloablative Allogeneic HLA-Identical Stem Cell Transplantation for CD4/CD56 Positive Acute Leukemia. <i>Transplantation</i> , 2007, 84, 1066-1067.	0.5	6

#	ARTICLE	IF	CITATIONS
127	Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. <i>Haematologica</i> , 2007, 92, 589-596.	1.7	95
128	Adapting Cyclosporine to Calcineurin Activity Rather Than to Cyclosporine Blood Levels: Toward a Functional Management of Graft-Versus-Host Disease Prophylaxis.. <i>Blood</i> , 2007, 110, 4990-4990.	0.6	0
129	Invasive Fungal Infection in Acute Leukemia Patients: What Is Their Impact on the Chemotherapy Schedule?.. <i>Blood</i> , 2007, 110, 4355-4355.	0.6	0
130	Ex Vivo-Expanded CD4+CD25+ Immunoregulatory T Cells Prevent Graft-versus-Host-Disease by Inhibiting Activation/Differentiation of Pathogenic T Cells. <i>Journal of Immunology</i> , 2006, 176, 1266-1273.	0.4	127
131	Empirical Versus Pre-Emptive Antifungal Therapy in High-Risk Febrile Neutropenic Patients: A Prospective Randomized Study.. <i>Blood</i> , 2006, 108, 2019-2019.	0.6	9
132	Empirical Versus Pre-Emptive Antifungal Therapy in High-Risk Febrile Neutropenic Patients: An Economic Analysis.. <i>Blood</i> , 2006, 108, 2021-2021.	0.6	2
133	Overcoming the Negative Impact of Age Using Fludarabine-Based Conditioning Regimens for HLA-Identical Sibling HSCT in Patients with Severe Aplastic Anemia (SAA): A Study from the EBMT-SAA Working Party.. <i>Blood</i> , 2006, 108, 3007-3007.	0.6	2
134	Unrelated Allogeneic Stem Cell Transplantation for Severe Acquired Aplastic Anemia: Has Outcome Improved?.. <i>Blood</i> , 2006, 108, 3105-3105.	0.6	2
135	Matched Unrelated Donor Stem Cell Transplantation for Patients with Diffuse Large Cell B Cell Lymphoma: A Retrospective Analysis of 118 Patients Registered through the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2006, 108, 602-602.	0.6	3
136	Applying the concept of healthcare-associated infections to hematology programs. <i>Haematologica</i> , 2006, 91, 1414-7.	1.7	9
137	Health Care-Associated Infection (HAI) Rates Are More Pertinent Quality Indicators Than Nosocomial Infection (NI) Ones for Hematology Programs.. <i>Blood</i> , 2005, 106, 5560-5560.	0.6	0
138	Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. <i>Blood</i> , 2002, 100, 2020-2025.	0.6	29
139	CHIMERISM ANALYSIS BY LINEAGE-SPECIFIC FLUORESCENT POLYMERASE CHAIN REACTION IN SECONDARY GRAFT FAILURE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION. <i>Transplantation</i> , 2001, 71, 374-380.	0.5	10
140	Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. <i>British Journal of Haematology</i> , 2001, 115, 630-641.	1.2	139
141	Successful Treatment of Disseminated Mucormycosis with Liposomal Amphotericin B and Surgery in a Child with Leukemia. <i>Clinical Infectious Diseases</i> , 1998, 26, 200-202.	2.9	33
142	Breakthrough Covid-19 infections in vaccinated recipients of allogeneic stem cell transplantation. <i>EJHaem</i> , 0, , .	0.4	1